Anti-Cisplatin modified DNA 抗体 [CP9/19] (ab103261)

ab103261 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab103261 は 8 報の論文で使用されています。

  • Hu J  et al. Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci U S A 113:11507-11512 (2016). PubMed: 27688757
  • Han C  et al. Differential DNA lesion formation and repair in heterochromatin and euchromatin. Carcinogenesis 37:129-38 (2016). PubMed: 26717995
  • Kumar S & Tchounwou PB Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells. Oncotarget 6:40734-46 (2015). ICC . PubMed: 26486083
  • Powell JR  et al. 3D-DIP-Chip: a microarray-based method to measure genomic DNA damage. Sci Rep 5:7975 (2015). ChIP . PubMed: 25609656
  • Rocha CR  et al. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505 (2014). Dot blot, ICC/IF ; Human . PubMed: 25356874
  • Lundholm L  et al. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis 4:e478 (2013). Flow Cyt ; Human . PubMed: 23370278
  • Jazaeri AA  et al. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 12:1958-67 (2013). PubMed: 23939375
  • Tilby MJ  et al. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res 51:123-9 (1991). PubMed: 1703029

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録